Encyclopedia of Clinical Neuropsychology

2018 Edition
| Editors: Jeffrey S. Kreutzer, John DeLuca, Bruce Caplan


  • Ethan MoitraEmail author
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-57111-9_115


Hemangioblastoma is a rare slow-growing neoplasm often found in the cerebellum, including in the posterior fossa region, or found in the spinal column. Symptoms may include ataxia, discoordination, headaches, nystagmus, and vomiting. Etiology is unknown as most arise spontaneously, but it may be linked to genetic abnormalities. In approximately one quarter of all cases, they are associated with von Hippel-Lindau disease (VHL), an autosomal dominant hereditary syndrome. Standard treatment is surgical excision, sometimes preceded by preoperative embolization to reduce vascularity. To avoid surgery in cases with high vascularity, recent studies have investigated nonsurgical approaches to treatment, such as the use of the β-blocker propranolol. Long-term prognosis is generally good, and recurrence risk is relatively low, even when associated with VHL.


References and Readings

  1. Albiñana, V., Villar-Gómez de las Heras, K., Serrano-Heras, G., Segura, T., & Belén Perona-Moratalla, A. (2015). Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients. Orphanet Journal of Rare Diseases, 10.  https://doi.org/10.1186/s13023-015-0343-5.
  2. Lonser, R., Glenn, G., Walther, M., Chew, E., Libutti, S., et al. (2003). von Hippel-Lindau disease. Lancet, 361, 2059–2067.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Psychiatry and Human BehaviorBrown UniversityProvidenceUSA